Truist Financial Corp Boosts Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Truist Financial Corp boosted its stake in shares of AtriCure, Inc. (NASDAQ:ATRC) by 2.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 15,717 shares of the medical device company’s stock after acquiring an additional 403 shares during the period. Truist Financial Corp’s holdings in AtriCure were worth $480,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ATRC. Creative Planning purchased a new position in AtriCure during the third quarter valued at $321,000. QRG Capital Management Inc. bought a new position in AtriCure during the third quarter valued at $276,000. Royce & Associates LP lifted its position in AtriCure by 8.0% during the third quarter. Royce & Associates LP now owns 64,785 shares of the medical device company’s stock valued at $1,817,000 after purchasing an additional 4,800 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new position in AtriCure during the third quarter valued at $880,000. Finally, Commerce Bank lifted its position in AtriCure by 23.5% during the third quarter. Commerce Bank now owns 11,470 shares of the medical device company’s stock valued at $322,000 after purchasing an additional 2,181 shares during the last quarter. 99.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Piper Sandler increased their price objective on shares of AtriCure from $40.00 to $50.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on shares of AtriCure from $40.00 to $51.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Oppenheimer increased their price objective on shares of AtriCure from $36.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, February 13th. Stifel Nicolaus increased their price objective on shares of AtriCure from $36.00 to $48.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Finally, Canaccord Genuity Group increased their price objective on shares of AtriCure from $61.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, AtriCure currently has an average rating of “Moderate Buy” and a consensus price target of $51.56.

AtriCure Price Performance

AtriCure stock opened at $38.96 on Tuesday. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $43.11. The firm has a 50-day moving average price of $37.36 and a 200-day moving average price of $32.85. The firm has a market capitalization of $1.90 billion, a PE ratio of -41.01 and a beta of 1.46. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.